| COR |
Report |
Adjusted diluted EPS (fiscal 2026 Q3) |
BEAT |
pred ~$4.42 vs. cons $4.35 |
MEDIUM |
| COR |
Report |
Revenue (fiscal 2026 Q3) |
MISS |
pred ~$83.2B vs. cons $84.1B |
MEDIUM |
| COR |
Report |
U.S. Healthcare Solutions segment operating income (fiscal 2026 Q3) |
BEAT |
pred ~$980M vs. cons $965M |
LOW |
| COR |
Guide |
Adjusted diluted EPS |
BETTER |
guide ~$17.83 vs. cons $17.79 (fiscal 2026 midpoint) |
MEDIUM |
| COR |
Guide |
Revenue growth |
LOWER |
guide ~4.5% vs. cons 4.9% (fiscal 2026 midpoint) |
MEDIUM |
| COR |
Guide |
U.S. Healthcare Solutions operating-income growth |
UNCHANGED |
guide ~15.0% vs. cons 15.0% (fiscal 2026 midpoint) |
MEDIUM |
| COR |
Guide |
Adjusted free cash flow |
UNCHANGED |
guide ~$3.0B vs. cons $3.0B (fiscal 2026) |
MEDIUM |
| COR |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.4% |
— |
MEDIUM |
| COR |
Return |
5-day cumulative residual |
+3.1% (FOLLOW-THROUGH) |
The predicted fiscal 2026 EPS-guide midpoint of ~$17.83 versus consensus of $17.79, combined with predicted Q3 EPS of ~$4.42, implies fiscal Q4 EPS of roughly $4.58 versus consensus near $4.53. That modestly positive out-period math should support upward revisions after the initial relief rally, while the revenue-guide reduction is likely discounted as predominantly low-margin mix pressure. |
MEDIUM |